Can I Have HoLEP If I Have Prostate Cancer?

← Back to the HoLEP overview

Short answer: often, yes. HoLEP treats the benign prostate enlargement that blocks urination; it does not treat prostate cancer. It can be a reasonable way to relieve obstruction while you remain on active surveillance, or before radiation in selected men. The sequence should be planned jointly by the HoLEP surgeon and the clinician treating the cancer.

Two problems in the same prostate

Benign prostatic hyperplasia (BPH) and prostate cancer can exist at the same time, but they are different diseases.

• HoLEP removes the enlarged inner part of the prostate—the transition-zone adenoma (the inner part of the prostate that enlarges with age and squeezes the urethra) that squeezes the urethra and causes a weak stream, incomplete emptying, retention, urgency, or nighttime urination.
• HoLEP leaves the outer prostate and surgical capsule in place. Most prostate cancers begin outside the tissue removed by HoLEP.
• The removed tissue is examined by a pathologist, but a benign HoLEP specimen does not rule out cancer elsewhere in the remaining prostate.

This is why HoLEP can improve urination without being a cancer operation. Cancer surveillance or treatment continues on its own track.

Where HoLEP can fit

If you are on active surveillance

The goal of active surveillance is to monitor a low-risk or selected favorable intermediate-risk cancer and treat it only if there is evidence of progression. BPH symptoms do not have to be ignored during that period.

The largest comparative study so far reviewed 310 men on active surveillance; 62 underwent HoLEP for lower urinary tract symptoms. Active surveillance was later discontinued in 18% of the HoLEP group and 56% of the group that did not undergo HoLEP. After adjustment, HoLEP was associated with a lower rate of leaving surveillance (hazard ratio (a measure of how much a treatment lowers risk over time) 0.231). Prostate-specific antigen (PSA) and PSA density were also lower after HoLEP.¹

That result is reassuring, but it does not prove that HoLEP prevents prostate cancer progression. The study was retrospective, the men were not randomly assigned, and the two groups differed at baseline. Removing a large amount of benign PSA-producing tissue can also change the tests and treatment thresholds used during surveillance. The safest conclusion is narrower: appropriately selected men can remain on active surveillance after HoLEP, with improved urination and a revised monitoring plan.

Earlier series point in the same direction:

• In 20 men with low-risk cancer on active surveillance, HoLEP substantially improved flow and bladder emptying. PSA fell from a median 8.5 ng/mL before surgery to 1.4 ng/mL at median 18.5-month follow-up. MRI and biopsy remained usable; two men with progression later underwent radical prostatectomy (surgical removal of prostate tissue, traditionally through an incision).²
• In a two-center series of 117 men with known localized prostate cancer, urinary symptoms and PSA improved after HoLEP. At median 30 months, 88 men (72%) remained on active surveillance and 27 received radiation with or without hormone therapy.³

Surveillance changes after HoLEP—it does not stop

After surgery, your cancer team may use:

1. a new postoperative PSA nadir and trend rather than comparing directly with the old PSA;
2. PSA density calculated from the prostate tissue that remains;
3. multiparametric MRI;
4. repeat biopsy when the cancer risk or surveillance protocol calls for it; and
5. the HoLEP pathology as additional information—not as a substitute for evaluating the remaining prostate.

A very low PSA after HoLEP is expected. A rising or persistently higher-than-expected PSA still deserves evaluation.

If radiation is planned

Radiation can temporarily worsen urinary frequency, urgency, burning, and obstruction. Men who begin radiation with severe symptoms, substantial obstruction, or a very large prostate may have more urinary difficulty during treatment. That creates a practical question: should the obstruction be treated first?

For selected men, HoLEP before radiation can:

• improve flow and bladder emptying;
• relieve catheter-dependent (a thin, flexible tube that drains urine from the bladder) retention;
• reduce the amount of benign tissue contributing to PSA and prostate volume; and
• establish better urinary function before radiation-related irritation begins.

The direct evidence is small but reassuring. In an 18-patient series, median prostate volume fell from 107 mL before HoLEP to 24 mL afterward, urinary symptoms improved, and subsequent external-beam radiation produced no grade 3 or higher acute or late urinary toxicity during median 18-month follow-up.⁴ A later 24-patient series found generally low incontinence burden and high urinary quality of life after radiation; one patient developed a bladder-neck contracture.⁵

Could HoLEP reduce radiation to healthy tissue?

We conducted a small study to estimate how HoLEP might change radiation exposure. Using CT scans from eight men with very large prostates, we created hypothetical radiation plans before and after HoLEP. The median volume of bladder receiving the full dose of radiation decreased by 47% after HoLEP, while rectal exposure did not change significantly.⁶

This suggests that HoLEP may reduce radiation delivered to healthy bladder tissue. The benefit remains theoretical: the study modeled radiation plans and did not test whether patients experienced fewer side effects.

This should not be translated into “everyone needs HoLEP before radiation.” Reviews emphasize that the evidence is retrospective and limited, while older transurethral resection of the prostate (TURP) literature raises concern for urinary toxicity after transurethral surgery. The decision depends on symptom severity, retention, prostate size, anatomy, radiation type, cancer risk, and the time available for healing.⁷

Practical rule: significant obstruction deserves a deliberate plan before radiation starts. Sometimes that plan is HoLEP; sometimes medication, hormone therapy, catheter management, or proceeding directly to radiation is better.

What if I may need cancer surgery later?

HoLEP does not close the door to future prostate cancer treatment. Radiation, radical prostatectomy, and selected focal therapies have all been performed after HoLEP.

But the options are not identical. A 2025 systematic review of 22 studies found that radical prostatectomy after HoLEP had similar cancer-pathology and erectile-function outcomes to prostatectomy without prior BPH surgery, but more intraoperative complications, more leakage at the bladder-to-urethra connection, and lower postoperative continence.⁸ These studies were mostly small, retrospective, and at moderate or high risk of bias, but the signal is important for counseling.

If radical prostatectomy is the likely cancer treatment, doing HoLEP first usually adds an operation without a clear benefit. If surveillance or radiation is the plan, HoLEP may have a more useful role.

What if cancer is found in the HoLEP specimen?

Incidental prostate cancer is found in roughly 5–13% of contemporary HoLEP series, and most detected cancers are low volume and Grade Group 1.⁹ The tissue result is useful, but it samples mainly the transition zone—not the entire prostate.

The next step may be surveillance, MRI, biopsy of the remaining prostate, radiation, or surgery. The decision depends on:

• Grade Group and how much of the specimen contains cancer;
• postoperative PSA and its trend;
• MRI findings;
• prior biopsy results;
• clinical stage, age, health, and life expectancy; and
• your preferences about surveillance versus treatment.

Questions to ask at the consultation

1. Are my urinary symptoms caused by benign obstruction, the cancer, the bladder, or more than one problem?
2. Is my cancer best managed with active surveillance, radiation, radical prostatectomy, or another approach?
3. If radiation is planned, would relieving the obstruction first improve the safety or tolerability of treatment?
4. How long should the prostate heal between HoLEP and radiation?
5. How will my PSA baseline and active-surveillance schedule change after HoLEP?
6. If my cancer progresses later, how would prior HoLEP affect my treatment options?

The bottom line

Prostate cancer does not automatically rule out HoLEP. HoLEP can relieve BPH obstruction while appropriately selected men continue active surveillance, and it can be considered before radiation when baseline obstruction is substantial. It does not remove or cure cancer, and it is usually not the right preliminary operation when radical prostatectomy is already the likely plan.

The best sequence is a coordinated decision between a HoLEP-experienced urologist and the prostate-cancer team.

If you are balancing prostate-cancer surveillance or radiation with significant urinary obstruction, schedule a discussion with Dr. Scott Quarrier about whether HoLEP belongs in the sequence of your care. Bring your PSA history, biopsy or pathology report, prostate MRI, and proposed cancer-treatment plan if available. Call (585) 275-2838 and ask to schedule with Dr. Quarrier.

Related guides

• How HoLEP works and who it is for
• Why choose HoLEP over other BPH procedures?
• What recovery looks like after HoLEP
• Frequently asked questions
• Research at UR Medicine

References